Last reviewed · How we verify
BRII-296
BRII-296 is a monoclonal antibody that targets the SARS-CoV-2 spike protein.
BRII-296 is a monoclonal antibody that targets the SARS-CoV-2 spike protein. Used for Treatment of COVID-19.
At a glance
| Generic name | BRII-296 |
|---|---|
| Sponsor | Brii Biosciences Limited |
| Drug class | Monoclonal antibody |
| Target | SARS-CoV-2 spike protein |
| Modality | Small molecule |
| Therapeutic area | Infectious disease |
| Phase | Phase 2 |
Mechanism of action
BRII-296 works by binding to the spike protein of the SARS-CoV-2 virus, preventing it from entering host cells and causing infection. This mechanism of action is similar to other monoclonal antibodies used to treat COVID-19.
Approved indications
- Treatment of COVID-19
Common side effects
- Injection site reaction
- Fatigue
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BRII-296 CI brief — competitive landscape report
- BRII-296 updates RSS · CI watch RSS
- Brii Biosciences Limited portfolio CI